House Passes Matsui's TRANSPLANT Act
WASHINGTON, D.C. — Today, the House of Representatives voted to pass Congresswoman Doris Matsui’s (CA-06) Timely ReAuthorization of Necessary Stem-cell Programs Lends Access to Needed Therapies (TRANSPLANT) Act (H.R. 941), a bill that reauthorizes the C.W. Bill Young Cell Transplantation Program (the Program) and the National Cord Blood Inventory for five years.
“Every three minutes, someone is diagnosed with a blood cancer. For patients and families facing these fatal diseases, a bone marrow or cord blood transplant may be the best treatment or only potential for a cure,” said Congresswoman Matsui. “For the 1.3 million Americans suffering from blood cancer and bone marrow disorders, we must continue to make investments in these programs that have saved tens of thousands of lives. I applaud my colleagues in the House for approving this bipartisan legislation and I urge the Senate to do the same.”
National Marrow Donor Program (NMDP) operates the federally authorized Program that matches unrelated volunteer bone marrow donors and cord blood units with patients who have been diagnosed with leukemia or over 70 otherwise fatal blood disorders and diseases. Never has the need to reauthorize the Program been more important than now, during the COVID-19 pandemic and in a time of rapidly evolving science and innovation in cell therapy. Through renewed federal funding for the Program, which includes the cord blood inventory, the TRANSPLANT Act ensures the continued, equal access provision of lifesaving transplants for patients in need of life-saving cellular therapy.
# # #